UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 4 von 53
Datensatz exportieren als...
BibTeX
Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer
Cancer, 2014-04, Vol.120 (8), p.1187-1193
Nogueira‐Rodrigues, Angelica
Moralez, Giulliana
Grazziotin, Rachele
Carmo, Claudio C.
Small, Isabele A.
Alves, Flavia V.G.
Mamede, Marcelo
Erlich, Felipe
Viegas, Celia
Triginelli, Sergio A.
Ferreira, Carlos G.
2014
Volltextzugriff (PDF)
Details
Autor(en) / Beteiligte
Nogueira‐Rodrigues, Angelica
Moralez, Giulliana
Grazziotin, Rachele
Carmo, Claudio C.
Small, Isabele A.
Alves, Flavia V.G.
Mamede, Marcelo
Erlich, Felipe
Viegas, Celia
Triginelli, Sergio A.
Ferreira, Carlos G.
Titel
Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer
Ist Teil von
Cancer, 2014-04, Vol.120 (8), p.1187-1193
Ort / Verlag
Hoboken, NJ: Wiley-Blackwell
Erscheinungsjahr
2014
Quelle
EZB-FREE-00999 freely available EZB journals
Beschreibungen/Notizen
BACKGROUND Cisplatin‐based chemoradiation (CRT) is the standard treatment for patients with locally advanced cervical cancer. Epidermal growth factor receptor (EGFR) is frequently overexpressed in cervical cancer, and EGFR inhibition itself has antitumor effects and potentiates CRT. Results of a previous phase 1 trial of the EGFR inhibitor erlotinib combined with cisplatin‐based CRT (E + CRT) recommended a phase 2 erlotinib dose of 150 mg/day. METHODS Eligibility criteria included International Federation of Gynecology and Obstetrics stage IIB to IIIB epidermoid cervical cancer, no prior therapy, and an Eastern Cooperative Oncology Group performance status of 0 to 2. Patients received erlotinib at a dose of 150 mg/day 1 week before and in combination with cisplatin (40 mg/m2 administered weekly for 5 cycles) and radiotherapy (4500 centigrays in 25 fractions), followed by brachytherapy (4 fractions at a dose of 600 centigrays weekly). RESULTS A total of 36 patients completed treatment with E + CRT. The median duration of therapy was 77 days and the median follow‐up period was 59.3 months. The therapy was well tolerated overall, and 34 patients (94.4%) achieved a complete response. The 2‐year and 3‐year cumulative overall and progression‐free survival rates were 91.7% and 80.6% and 80% and 73.8%, respectively. CONCLUSIONS Treatment with E + CRT appears to be safe and exerts significant activity against locally advanced cervical cancer. To the best of the authors' knowledge, this is the first study to date to demonstrate that a target agent has promising activity against locally advanced cervical cancer. Cancer 2014;120:1187–1193. © 2014 American Cancer Society. According to this phase 2 trial, erlotinib combined with chemoradiation is safe and exerts significant activity in patients with locally advanced cervical cancer. To the best of the authors' knowledge, this is the first study to date to demonstrate that a target agent has promising activity in this disease.
Sprache
Englisch
Identifikatoren
ISSN: 0008-543X
eISSN: 1097-0142
DOI: 10.1002/cncr.28471
Titel-ID: cdi_proquest_miscellaneous_1514430433
Format
–
Schlagworte
Adult
,
Aged
,
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
,
Biological and medical sciences
,
Brachytherapy
,
cervical cancer
,
Chemoradiotherapy
,
chemotherapy
,
Cisplatin - administration & dosage
,
Cisplatin - adverse effects
,
clinical trial
,
erlotinib
,
Erlotinib Hydrochloride
,
Female
,
Female genital diseases
,
Gynecology. Andrology. Obstetrics
,
Humans
,
Medical sciences
,
Middle Aged
,
Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
,
Neoplasm Staging
,
phase 2
,
Protein Kinase Inhibitors - administration & dosage
,
Protein Kinase Inhibitors - adverse effects
,
Quinazolines - administration & dosage
,
Quinazolines - adverse effects
,
radiotherapy
,
Receptor, Epidermal Growth Factor - antagonists & inhibitors
,
Tumors
,
Uterine Cervical Neoplasms - mortality
,
Uterine Cervical Neoplasms - pathology
,
Uterine Cervical Neoplasms - therapy
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX